A Record Number of Therapies for Cancer Currently in Development - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

A Record Number of Therapies for Cancer Currently in Development


ePT--the Electronic Newsletter of Pharmaceutical Technology

Nearly 900 therapies for the treatment, diagnosis, or prevention of cancer are currently in development, according to a report released by the Pharmaceutical Research and Manufacturers of America (PhRMA). This is more than double the number of therapies that were in development six years ago. 

Underlying the increase is a greater understanding at the genetic level of the causes of cancer, and advances in research on the cellular mechanisms underlying tumor growth and metastasis. This has paved the way for targeted therapy: therapies directed toward specific features of tumor growth and survival. For example, therapies are being developed that interfere with vascularization of tumors, and others are being developed that  deprive tumors of energy derived from glucose. The hope is that these specific treatments will be effective but have less general toxicity than current treatments. 

The list of development candidates includes a variety of potential therapeutics other than small-molecule therapeutics. Biologics, including vaccines and antibody treatments (monoclonals, polyclonals and antibody fusion constructs), are well represented.  Gene therapy, antisense treatment, and a therapy using encapsulated cells are also in development. The inclusion of biologics increases the arsenal available to pharmaceutical developers, according to the PhRMA report.

According to the report, cancer occurs in many forms, and one medication does not fit all. Despite gains made in treatment, particularly of breast and prostate cancer, cancer remains the second leading cause of death in the United States. Pharmaceutical manufacturers have certainly recognized the unmet medical need, and are responding.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
25%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
11%
Regulatory compliance
36%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here